Sandoz's Biosimilar Shows Similarity to Amgen's Neupogen

Published on: 

Sandoz announces their version of filgrastim, a follow-on biologic for the treatment of neutropenia, is as safe and effective as Amgen's Neupogen.

 

 

 

Related Content:

Biosimilars and BiobettersManufacturing, Biosimilars and BiobettersBiopharma News
CureVac and MD Anderson Cancer Center Collaborate on mRNA Cancer Vaccines
Genmab to Acquire ProfoundBio in $1.8 Billion Deal, Gains ADC Pipeline
FDA Grants Fast Track Designation to J&J’s Nipocalimab for Rare Disease